Skip to content

Therapeutic effect of granulocyte colony-stimulating factor in patients with acute traumatic spinal cord injury

A comparison between therapeutic effect of granulocyte colony-stimulating factor and methylprednisolone on sensory and motor function in patients with acute traumatic spinal cord injury

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT201504077369N2
Enrollment
92
Registered
2015-08-17
Start date
2013-05-29
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Traumatic spinal cord injury. Condition 2: Traumatic spinal cord injury. Condition 3: Traumatic spinal cord injury. Condition 4: Traumatic spinal cord injury. Condition 5: Traumatic spinal cord injury. Transport accidents Other external causes of accidental injury Other and unspecified injuries of thoracic spinal cord Other and unspecified injuries of cervical spinal cord Sequelae of injury of spinal cord

Interventions

Intervention 1: Intravenous infusion of 10 microgram/kg/day G-CSF for 5 consecutive days. Intervention 2: Methylprednisolone is given as an initial intravenous bolus of 30 mg/kg administered over a pe
if treatment is begun between 3 to 8 hours after injury, the infusion is continued for 47 hours (for a total of 48 hours).
Treatment - Drugs
Intravenous infusion of 10 microgram/kg/day G-CSF for 5 consecutive days
Methylprednisolone is given as an initial intravenous bolus of 30 mg/kg administered over a period of 15 minutes. This is followed 45 minutes later by a 5.4 mg/kg per hour continuous infusion of methy

Sponsors

Vice Chancellor for Research and Technology of Guilan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Acute traumatic spinal cord injury; Age between 18 to 65 years old Exclusion criteria: Presence of intracranial lesions such as tumor, infection, ischemia or trauma; Past history of massive blood loss with transfusion; Past history of leukopenia or thrombocytopenia; Past history of hepatic or renal dysfunction; Past history of sever heart failure; Presence of splenomegaly or past history of it; Any evidence of malignancy during past 5 years; Pregnancy or lactation

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Spinal cord injury grade. Timepoint: Before the intervention, 1 week after the intervention, 3 months after the intervention and 6 months after the intervention. Method of measurement: AIS grading system.;Sensory and motor function score. Timepoint: Before the intervention, 1 week after the intervention, 3 months after the intervention and 6 months after the intervention. Method of measurement: ASIA scoring system.

Secondary

MeasureTime frame
-. Timepoint: -. Method of measurement: -.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSiavash Dehghani

Guilan University of Medical Sciences

dr.sia_sur@yahoo.com+98 918 832 4416

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026